Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Circ Res
2010 Aug 20;1074:532-9. doi: 10.1161/CIRCRESAHA.110.217075.
Show Gene links
Show Anatomy links
Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure.
Casey LM
,
Pistner AR
,
Belmonte SL
,
Migdalovich D
,
Stolpnik O
,
Nwakanma FE
,
Vorobiof G
,
Dunaevsky O
,
Matavel A
,
Lopes CM
,
Smrcka AV
,
Blaxall BC
.
???displayArticle.abstract???
Excess signaling through cardiac Gbetagamma subunits is an important component of heart failure (HF) pathophysiology. They recruit elevated levels of cytosolic G protein-coupled receptor kinase (GRK)2 to agonist-stimulated beta-adrenergic receptors (beta-ARs) in HF, leading to chronic beta-AR desensitization and downregulation; these events are all hallmarks of HF. Previous data suggested that inhibiting Gbetagamma signaling and its interaction with GRK2 could be of therapeutic value in HF. We sought to investigate small molecule Gbetagamma inhibition in HF. We recently described novel small molecule Gbetagamma inhibitors that selectively block Gbetagamma-binding interactions, including M119 and its highly related analog, gallein. These compounds blocked interaction of Gbetagamma and GRK2 in vitro and in HL60 cells. Here, we show they reduced beta-AR-mediated membrane recruitment of GRK2 in isolated adult mouse cardiomyocytes. Furthermore, M119 enhanced both adenylyl cyclase activity and cardiomyocyte contractility in response to beta-AR agonist. To evaluate their cardiac-specific effects in vivo, we initially used an acute pharmacological HF model (30 mg/kg per day isoproterenol, 7 days). Concurrent daily injections prevented HF and partially normalized cardiac morphology and GRK2 expression in this acute HF model. To investigate possible efficacy in halting progression of preexisting HF, calsequestrin cardiac transgenic mice (CSQ) with extant HF received daily injections for 28 days. The compound alone halted HF progression and partially normalized heart size, morphology, and cardiac expression of HF marker genes (GRK2, atrial natriuretic factor, and beta-myosin heavy chain). These data suggest a promising therapeutic role for small molecule inhibition of pathological Gbetagamma signaling in the treatment of HF.
???displayArticle.pubmedLink???
20576935
???displayArticle.pmcLink???PMC2924955 ???displayArticle.link???Circ Res ???displayArticle.grants???[+]
Blaxall,
Differential gene expression and genomic patient stratification following left ventricular assist device support.
2003, Pubmed
Blaxall,
Differential gene expression and genomic patient stratification following left ventricular assist device support.
2003,
Pubmed
Bonacci,
Differential targeting of Gbetagamma-subunit signaling with small molecules.
2006,
Pubmed
Bristow,
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.
1982,
Pubmed
Cho,
Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression.
1999,
Pubmed
Dorn,
GRK mythology: G-protein receptor kinases in cardiovascular disease.
2009,
Pubmed
Eckhart,
Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure.
2002,
Pubmed
Gros,
G-Protein-coupled receptor kinase activity in hypertension : increased vascular and lymphocyte G-protein receptor kinase-2 protein expression.
2000,
Pubmed
Gros,
G-protein-coupled receptor kinase expression in hypertension.
1999,
Pubmed
Harding,
Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure.
2001,
Pubmed
Hata,
Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease.
2003,
Pubmed
Hata,
Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading.
2006,
Pubmed
Hippe,
Activation of heterotrimeric G proteins by a high energy phosphate transfer via nucleoside diphosphate kinase (NDPK) B and Gbeta subunits. Specific activation of Gsalpha by an NDPK B.Gbetagamma complex in H10 cells.
2003,
Pubmed
Hunt,
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.
2005,
Pubmed
Iaccarino,
Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade.
1998,
Pubmed
Iaccarino,
Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation.
1999,
Pubmed
Koch,
Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor.
1995,
Pubmed
Lefkowitz,
Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins.
1993,
Pubmed
Lehmann,
Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation.
2008,
Pubmed
Li,
Effects of two Gbetagamma-binding proteins--N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure.
2003,
Pubmed
Lloyd-Jones,
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
2009,
Pubmed
Lorenz,
A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.
2009,
Pubmed
Lymperopoulos,
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure.
2007,
Pubmed
Matkovich,
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling.
2006,
Pubmed
McKinsey,
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface.
2007,
Pubmed
Nienaber,
Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.
2003,
Pubmed
Penela,
Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease.
2006,
Pubmed
Perrino,
Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex.
2005,
Pubmed
Perrino,
Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression.
2005,
Pubmed
Pitcher,
Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors.
1992,
Pubmed
Raake,
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.
2008,
Pubmed
Rockman,
Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.
1998,
Pubmed
Rockman,
Seven-transmembrane-spanning receptors and heart function.
2002,
Pubmed
Rockman,
Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice.
1998,
Pubmed
Ungerer,
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.
1993,
Pubmed
Williams,
Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts.
2004,
Pubmed